Stoke Therapeutics Upsizes ATM to $200M, Replaces Prior Prospectus

summarizeSummary

Stoke Therapeutics filed a prospectus supplement for its upsized $200 million at-the-market equity program, replacing the prior $150 million program after selling $146.4 million in shares.

check_boxKey Events · Financing and Capital Events · STOK

• ATM Program Upsized to $200M

  The prospectus supplement registers up to $200 million in common stock sales through Cantor Fitzgerald, replacing the prior $150 million program.

• Prior Sales Total $146.4M

  Under the previous prospectus supplement, 4.7 million shares were sold for aggregate net proceeds of $146.4 million.

• Dilution Risk Remains

  Assuming sales at $28.86 per share, new investors would experience immediate dilution of $21.05 per share, and the ATM overhang could pressure the stock.

• Use of Proceeds for General Purposes

  Net proceeds will fund research, clinical development, manufacturing, working capital, and potential acquisitions, with no specific allocation.

auto_awesomeAnalysis · STOK · Life Sciences

Stoke Therapeutics filed a final prospectus supplement for its upsized at-the-market equity program, increasing the aggregate offering price to $200 million from the prior $150 million. The company has already sold 4.7 million shares for $146.4 million in net proceeds under the previous program. The new supplement replaces the March 2026 prospectus and allows continued sales through Cantor Fitzgerald. While the ATM provides flexible access to capital, the ongoing dilution and the upsizing signal a continued need for funding, which is notable given the company's recent revenue decline and net losses.